MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Home・Akcijų sąrašas・Avita Therapeutics Inc

Avita Therapeutics Inc

Uždarymo kaina

3.87 12.83

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.43

Max

3.92

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-3.3M -13M
Pardavimai	-1.4M 17M
Pelno marža	-77.289
Darbuotojai	260
EBITDA	-3.2M -11M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+30.06% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-12

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-15M 106M
Ankstesnė atidarymo kaina	-8.96
Ankstesnė uždarymo kaina	3.87

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

8.83 / 9.77 Palaikymas ir pasipriešinimas

Avita Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-16 23:29; UTC

Karštos akcijos

Stocks to Watch: Atossa Therapeutics, Union Pacific

2026-01-16 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

2026-01-16 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

2026-01-16 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

2026-01-16 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Auto & Transport Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-16 21:48; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

2026-01-16 21:41; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

2026-01-16 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

2026-01-16 20:44; UTC

Uždarbis

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

2026-01-16 20:42; UTC

Rinkos pokalbiai

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

2026-01-16 20:28; UTC

Rinkos pokalbiai

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

2026-01-16 19:12; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

2026-01-16 18:53; UTC

Rinkos pokalbiai

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

2026-01-16 18:41; UTC

Rinkos pokalbiai

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

2026-01-16 18:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-16 17:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-16 17:03; UTC

Rinkos pokalbiai

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

2026-01-16 16:32; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

2026-01-16 16:20; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Avita Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

30.06% į viršų

12 mėnesių prognozė

Vidutinis 4.5 USD 30.06%

Aukščiausias 5.5 USD

Žemiausias 3.5 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Avita Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Avita Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

8.83 / 9.77Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.